Details
Stereochemistry | ACHIRAL |
Molecular Formula | C21H30N4O5S |
Molecular Weight | 450.552 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
COC1=CC(O)=C(C=C1OC)C(=O)NC2=NC(=CS2)C(=O)NCCN(C(C)C)C(C)C
InChI
InChIKey=TWHZNAUBXFZMCA-UHFFFAOYSA-N
InChI=1S/C21H30N4O5S/c1-12(2)25(13(3)4)8-7-22-20(28)15-11-31-21(23-15)24-19(27)14-9-17(29-5)18(30-6)10-16(14)26/h9-13,26H,7-8H2,1-6H3,(H,22,28)(H,23,24,27)
Molecular Formula | C21H30N4O5S |
Molecular Weight | 450.552 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/23881665Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21123674 | https://www.ncbi.nlm.nih.gov/pubmed/10871292 | https://www.astellas.com/en/corporate/news/pdf/130605_1_Eg.pdf
Sources: https://www.ncbi.nlm.nih.gov/pubmed/23881665
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/21123674 | https://www.ncbi.nlm.nih.gov/pubmed/10871292 | https://www.astellas.com/en/corporate/news/pdf/130605_1_Eg.pdf
Acotiamide (Acofide(®)), an oral first-in-class prokinetic drug, is under global development by Zeria Pharmaceutical Co. Ltd and Astellas Pharma Inc. for the treatment of patients with functional dyspepsia. The drug modulates upper gastrointestinal motility to alleviate abdominal symptoms resulting from hypomotility and delayed gastric emptying. It exerts its activity in the stomach via muscarinic receptor inhibition, resulting in enhanced acetylcholine release and inhibition of acetylcholinesterase activity. Acofide® is launched in Japan for treating functional dyspepsia.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL220 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21123674 |
3.0 µM [IC50] | ||
Target ID: CHEMBL276 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10871292 |
|||
Target ID: CHEMBL211 Sources: https://www.ncbi.nlm.nih.gov/pubmed/10871292 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ACOFIDE Approved UseAcofide (Acotiamide hydrochloride hydrate) improves gastrointestinal motility and promotes excretion of stomach contents by inhibiting acetylcholinesterase activities.
It is usually used for the treatment of postprandial fullness, upper abdominal bloating, and early satiation due to functional dyspepsia. Launch Date2013 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
25.71 ng/mL |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
ACOTIAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
200 ng/mL OTHER GOV'T https://www.pmda.go.jp/files/000153467.pdf |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
ACOTIAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
168.2 ng/mL OTHER GOV'T https://www.pmda.go.jp/files/000153467.pdf |
300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ACOTIAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
451.59 ng/mL OTHER GOV'T https://www.pmda.go.jp/files/000153467.pdf |
900 mg 3 times / day multiple, oral dose: 900 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ACOTIAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
511.75 ng × h/mL |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
ACOTIAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
537.2 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/files/000153467.pdf |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
ACOTIAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1215 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/files/000153467.pdf |
300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ACOTIAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
1659.57 ng × h/mL OTHER GOV'T https://www.pmda.go.jp/files/000153467.pdf |
900 mg 3 times / day multiple, oral dose: 900 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ACOTIAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
23.49 h |
100 mg single, oral dose: 100 mg route of administration: Oral experiment type: SINGLE co-administered: |
ACOTIAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
8.99 h OTHER GOV'T https://www.pmda.go.jp/files/000153467.pdf |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
ACOTIAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
11.25 h OTHER GOV'T https://www.pmda.go.jp/files/000153467.pdf |
300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ACOTIAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
14.92% OTHER GOV'T https://www.pmda.go.jp/files/000153467.pdf |
300 mg single, oral dose: 300 mg route of administration: Oral experiment type: SINGLE co-administered: |
ACOTIAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
14.92% OTHER GOV'T https://www.pmda.go.jp/files/000153467.pdf |
300 mg 3 times / day multiple, oral dose: 300 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ACOTIAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
14.92% OTHER GOV'T https://www.pmda.go.jp/files/000153467.pdf |
900 mg 3 times / day multiple, oral dose: 900 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
ACOTIAMIDE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Other AEs: Constipation, Diarrhea... Other AEs: Constipation (2.2%) Sources: Diarrhea (2.2%) ALT increased (1.5%) Gamma-glutamyltransferase increased (1%) |
100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Disc. AE: Nausea, Dyspepsia... AEs leading to discontinuation/dose reduction: Nausea (1.4%) Sources: Dyspepsia (0.97%) Constipation (0.48%) Eructation (0.48%) Gastrointestinal sounds abnormal (0.48%) Reflux gastritis (0.48%) Appetite decreased NOS (0.48%) Dysgeusia (0.48%) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Gamma-glutamyltransferase increased | 1% | 100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
ALT increased | 1.5% | 100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Constipation | 2.2% | 100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Diarrhea | 2.2% | 100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Appetite decreased NOS | 0.48% Disc. AE |
100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Constipation | 0.48% Disc. AE |
100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Dysgeusia | 0.48% Disc. AE |
100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Eructation | 0.48% Disc. AE |
100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Gastrointestinal sounds abnormal | 0.48% Disc. AE |
100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Reflux gastritis | 0.48% Disc. AE |
100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Dyspepsia | 0.97% Disc. AE |
100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Nausea | 1.4% Disc. AE |
100 mg 3 times / day multiple, oral Recommended Dose: 100 mg, 3 times / day Route: oral Route: multiple Dose: 100 mg, 3 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no [Ki 1030.8 uM] | ||||
no [Ki 140.5 uM] | ||||
no [Ki 225.5 uM] | ||||
no [Ki 2624.7 uM] | ||||
no [Ki >10000 uM] | ||||
no | ||||
weak |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
major [Km 1430 uM] | ||||
major [Km 43.13 uM] | ||||
Page: 30.0 |
major | |||
Page: 30.0 |
minor | |||
Page: 30.0 |
minor | |||
Page: 30.0 |
no | |||
Page: 30.0 |
no | |||
Page: 30.0 |
no | |||
Page: 30.0 |
no | |||
Page: 23.0 |
weak [Km 697 uM] | |||
Page: 30.0 |
weak | |||
Page: 30.0 |
weak | |||
Page: 30.0 |
weak | |||
Page: 30.0 |
weak | |||
Page: 30.0 |
weak | |||
Page: 30.0 |
weak | |||
weak | ||||
weak | ||||
weak | ||||
weak | ||||
weak | ||||
weak | ||||
weak |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Prokinetics and fundic relaxants in upper functional GI disorders. | 2008 Dec |
|
[Functional and motor gastrointestinal disorders]. | 2008 Oct |
|
Acotiamide hydrochloride (Z-338), a novel prokinetic agent, restores delayed gastric emptying and feeding inhibition induced by restraint stress in rats. | 2008 Sep |
|
A dose-ranging, placebo-controlled, pilot trial of Acotiamide in patients with functional dyspepsia. | 2009 Mar |
|
Acotiamide (Z-338) as a possible candidate for the treatment of functional dyspepsia. | 2010 Jun |
|
Clinical trial: dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia - 100 mg t.i.d. is an optimal dosage. | 2010 Jun |
Patents
Sample Use Guides
In general, for adults, take 1 tablet (100mg of the active ingredient) at a time, 3 times a day before meals.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/26418413
Acotiamide (0.3 and 1 uM) significantly enhanced the contraction of guinea pig gastric body strips induced by electrical field stimulation
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:28:00 GMT 2025
by
admin
on
Mon Mar 31 18:28:00 GMT 2025
|
Record UNII |
D42OWK5383
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C267
Created by
admin on Mon Mar 31 18:28:00 GMT 2025 , Edited by admin on Mon Mar 31 18:28:00 GMT 2025
|
||
|
NCI_THESAURUS |
C47792
Created by
admin on Mon Mar 31 18:28:00 GMT 2025 , Edited by admin on Mon Mar 31 18:28:00 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
8506
Created by
admin on Mon Mar 31 18:28:00 GMT 2025 , Edited by admin on Mon Mar 31 18:28:00 GMT 2025
|
PRIMARY | |||
|
C65214
Created by
admin on Mon Mar 31 18:28:00 GMT 2025 , Edited by admin on Mon Mar 31 18:28:00 GMT 2025
|
PRIMARY | |||
|
CHEMBL2107723
Created by
admin on Mon Mar 31 18:28:00 GMT 2025 , Edited by admin on Mon Mar 31 18:28:00 GMT 2025
|
PRIMARY | |||
|
m1383
Created by
admin on Mon Mar 31 18:28:00 GMT 2025 , Edited by admin on Mon Mar 31 18:28:00 GMT 2025
|
PRIMARY | |||
|
185106-16-5
Created by
admin on Mon Mar 31 18:28:00 GMT 2025 , Edited by admin on Mon Mar 31 18:28:00 GMT 2025
|
PRIMARY | |||
|
D42OWK5383
Created by
admin on Mon Mar 31 18:28:00 GMT 2025 , Edited by admin on Mon Mar 31 18:28:00 GMT 2025
|
PRIMARY | |||
|
5282338
Created by
admin on Mon Mar 31 18:28:00 GMT 2025 , Edited by admin on Mon Mar 31 18:28:00 GMT 2025
|
PRIMARY | |||
|
DTXSID40870163
Created by
admin on Mon Mar 31 18:28:00 GMT 2025 , Edited by admin on Mon Mar 31 18:28:00 GMT 2025
|
PRIMARY | |||
|
DB12482
Created by
admin on Mon Mar 31 18:28:00 GMT 2025 , Edited by admin on Mon Mar 31 18:28:00 GMT 2025
|
PRIMARY | |||
|
ACOTIAMIDE
Created by
admin on Mon Mar 31 18:28:00 GMT 2025 , Edited by admin on Mon Mar 31 18:28:00 GMT 2025
|
PRIMARY | |||
|
300000036947
Created by
admin on Mon Mar 31 18:28:00 GMT 2025 , Edited by admin on Mon Mar 31 18:28:00 GMT 2025
|
PRIMARY | |||
|
4908
Created by
admin on Mon Mar 31 18:28:00 GMT 2025 , Edited by admin on Mon Mar 31 18:28:00 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
|
||
|
TARGET -> INHIBITOR |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|